Announcement on behalf of OBIGEN that it has achieved the objectives of interim analysis for Phase 2 clinical trial of OBI-858

Date of occurrence of the event:2025/03/20 New drug name or code:OBI-858 Novel Botulinum Neurotoxin Indication: OBI-858, an in-house developed novel botulinum neurotoxin (BoNT) product, is planned for aesthetic and therapeutic uses. Patents for its special molecular weight have been granted in Taiwan, Australia, New Zealand, Japan, Russia, Kingdom of Saudi Arabia, Indonesia, Malaysia, and Singapore. […]